Lung Cancer — Small Cell (SCLC) Clinical Trials

About Lung Cancer — Small Cell (SCLC) trials

SCLC trials test for a relatively small set of biomarkers because most SCLC trial eligibility depends on stage, prior treatment, and clinical fitness more than on molecular profile. PD-L1 (CD274) status is tested but IO is now standard front-line for extensive-stage SCLC regardless of PD-L1 expression. BRCA1 and BRCA2 mutations are uncommon in SCLC but actionable for PARP inhibitor trials when present. EGFR, ROS1, and ALK alterations are very rare in SCLC but matter most in two contexts: tumors that transformed from NSCLC during targeted therapy resistance (typically EGFR-mutant adenocarcinomas that converted to SCLC under osimertinib pressure), and rare de novo cases. MET, HER2 (ERBB2), and KRAS alterations are similarly uncommon in SCLC but cover the small subset of patients who may qualify for solid-tumor-based targeted trials.

Recruiting trials cluster by stage and treatment line. Limited-stage SCLC (LS-SCLC) trials test additions to concurrent chemoradiation, with durvalumab consolidation now standard (ADRIATIC) for patients whose disease has not progressed after concurrent platinum-based chemotherapy and radiation. Extensive-stage SCLC (ES-SCLC) front-line trials test additions to platinum + etoposide + IO, the current standard. Maintenance trials test PARP inhibitors, lurbinectedin, novel agents, and IO continuations after induction. Second-line trials are an active space, with lurbinectedin combinations, tarlatamab (DLL3 bispecific) combinations, and novel mechanisms competing. DLL3-targeted trials are a major emerging area following tarlatamab approval, with multiple DLL3-directed bispecifics, CAR-Ts, and ADCs in development. Transformed SCLC trials enroll patients whose disease evolved from NSCLC during targeted-therapy resistance, often testing approaches that bridge NSCLC and SCLC biology. PARP inhibitor trials enroll BRCA-mutated SCLC patients (a small but identifiable subgroup).

Beyond biomarkers, SCLC trial eligibility depends on stage, prior platinum chemotherapy, and prior IO and DLL3-targeted therapy exposure. Stage (limited stage vs extensive stage) determines which trials apply. Prior platinum chemotherapy is the backbone of front-line SCLC, and most R/R trials specify either platinum-sensitive (relapse >90 days from last platinum) or platinum-resistant relapse. Prior immunotherapy exposure: most R/R trials are IO-pretreated specific because IO is now standard front-line. Prior tarlatamab or other DLL3-targeted therapy exposure is a newly relevant criterion as DLL3 trials multiply. Brain metastasis status, where many SCLC trials require treated and stable brain mets given how often SCLC involves the CNS. Performance status, with most trials accepting ECOG 0-1, sometimes ECOG 2 for second-line trials. Prior radiation exposure (especially thoracic) for trials testing radiation-based combinations.

Biomarkers tested in Lung Cancer — Small Cell (SCLC) trials

These are the molecular markers most commonly required or evaluated in Lung Cancer — Small Cell (SCLC) eligibility criteria. OncoMatch extracts them from each trial's protocol and matches them against your test results.